200 related articles for article (PubMed ID: 35774429)
1. Current status and progress in immunotherapy for malignant pleural mesothelioma.
Sun B; Dong Y; Xu J; Wang Z
Chronic Dis Transl Med; 2022 Jun; 8(2):91-99. PubMed ID: 35774429
[TBL] [Abstract][Full Text] [Related]
2. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
3. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
Terenziani R; Zoppi S; Fumarola C; Alfieri R; Bonelli M
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199722
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J; Dundar Y; Dodd S; Dickson R; Walley T
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005574. PubMed ID: 17253564
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
7. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D; Sterman DH
Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
Cinausero M; Rihawi K; Sperandi F; Melotti B; Ardizzoni A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S304-S310. PubMed ID: 29507800
[TBL] [Abstract][Full Text] [Related]
11. Emerging biological therapies for the treatment of malignant pleural mesothelioma.
Davis AP; Kao SC; Clarke SJ; Boyer M; Pavlakis N
Expert Opin Emerg Drugs; 2021 Jun; 26(2):179-192. PubMed ID: 33945357
[No Abstract] [Full Text] [Related]
12. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
13. [Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma].
Huang Y; Meng Q
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):441-446. PubMed ID: 34157803
[TBL] [Abstract][Full Text] [Related]
14. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
15. Tsunami of immunotherapy reaches mesothelioma.
Mielgo-Rubio X; Cardeña Gutiérrez A; Sotelo Peña V; Sánchez Becerra MV; González López AM; Rosero A; Trujillo-Reyes JC; Couñago F
World J Clin Oncol; 2022 Apr; 13(4):267-275. PubMed ID: 35582652
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
17. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).
Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C
Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640
[TBL] [Abstract][Full Text] [Related]
19. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
Facchetti G; Petrella F; Spaggiari L; Rimoldi I
Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
Remon J; Reguart N; Corral J; Lianes P
Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
